Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Severe Interstitial Lung Disease With First‐Line Enfortumab Vedotin Plus Pembrolizumab in Japanese Real‐World Practice. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa2312117
10.1056/nejmoa2312117 · External reference
10.3390/cancers18050739
10.3390/cancers18050739 · External reference
Increased Risk of Interstitial Lung Disease With Enfortumab Vedotin Plus Pembrolizumab Compared With Sequential Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan
2026 · External reference
10.1093/jjco/hyaf182
10.1093/jjco/hyaf182 · External reference
Unresolved reference
2024 · External reference
